Celltrion (068270) Q4 2025 earnings summary

Executive summary

• Achieved record-high annual revenue exceeding KRW 4 trillion, up 17% year-over-year, and record-high operating profit surpassing KRW 1 trillion, up 137.5% year-over-year.

• Young portfolio contributed 54% of revenue in 2025, up from 38% in 2024, driven by rapid uptake of five new product launches.

• U.S. manufacturing facility acquisition eliminated tariff risks and diversified production sites.

• Significant shareholder returns: KRW 840bn in treasury shares acquired, KRW 900bn cancelled, and KRW 750/share cash dividend.

Financial highlights

• 4Q25 sales reached KRW 1,330.2bn, up 25.1% year-over-year and 29.3% sequentially; operating profit was KRW 475.2bn, up 142% year-over-year and 57.7% sequentially.

• Gross profit margin for 2025 was 59.3%, up 12 percentage points year-over-year; operating profit margin rose to 28.1%, up 14.3 percentage points.

• Net profit for 2025 was KRW 1,032bn, up 146.2% year-over-year, with a net profit margin of 24.8%.

• Biologics sales grew 24.3% year-over-year to KRW 3,864bn; young products sales surged 73.6% to KRW 2,071bn.

Outlook and guidance

• 2026 sales guidance set at KRW 5.3 trillion, representing 26% year-over-year growth.

• Young portfolio expected to account for up to 70% of biologics sales in 2026.

• U.S. launches of Omlyclo and Eydenzelt and new indication for Steqeyma planned for 2H26.

• Pipeline expansion with 8 disclosed biosimilar programs and new drug milestones anticipated.